NCT01609075

Brief Summary

This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and Avastin will be followed for up to 15 months.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
437

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2012

Shorter than P25 for all trials

Geographic Reach
1 country

72 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 29, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 31, 2012

Completed
1 day until next milestone

Study Start

First participant enrolled

June 1, 2012

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

November 2, 2016

Status Verified

November 1, 2016

Enrollment Period

1 year

First QC Date

May 29, 2012

Last Update Submit

November 1, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events

    approximately 15 months

Secondary Outcomes (4)

  • Proportion of patients with treatment discontinuation due to other causes

    approximately 15 months

  • Incidence of other causes for treatment discontinuation

    approximately 15 months

  • Second-line treatments initiated

    approximately 15 months

  • Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes)

    approximately 15 months

Study Arms (1)

Cohort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with metastatic colorectal cancer having initiated first-line treatment with fluoropyrimidine-based chemotherapy and Avastin

You may qualify if:

  • Adult patients, \>/= 18 years of age
  • Metastatic colorectal cancer
  • Having initiated first-line treatment with fluoropyrimidine-based chemotherapy plus Avastin between 1. September 2011 and 29. February 2012
  • Availability of test fro K-RAS genotyping

You may not qualify if:

  • Participation in a clinical trial during treatment with Avastin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (72)

Unknown Facility

L’Aquila, Abruzzo, 67010, Italy

Location

Unknown Facility

Teramo, Abruzzo, 64100, Italy

Location

Unknown Facility

Brindisi, Apulia, 72100, Italy

Location

Unknown Facility

Castellana Grotte (BA), Apulia, 70013, Italy

Location

Unknown Facility

Foggia, Apulia, 71100, Italy

Location

Unknown Facility

Lecce, Apulia, 73100, Italy

Location

Unknown Facility

San Giovanni Rotondo, Apulia, 71013, Italy

Location

Unknown Facility

Rionero in Vulture, Basilicate, 85028, Italy

Location

Unknown Facility

Cosenza, Calabria, 87100, Italy

Location

Unknown Facility

Lamezia Terme (CZ), Calabria, 88046, Italy

Location

Unknown Facility

Reggio Calabria, Calabria, 89100, Italy

Location

Unknown Facility

Benevento, Campania, 82100, Italy

Location

Unknown Facility

Napoli, Campania, 80100, Italy

Location

Unknown Facility

Napoli, Campania, 80131, Italy

Location

Unknown Facility

Pagani ( Sa), Campania, 84016, Italy

Location

Unknown Facility

Imola (BO), Emilia-Romagna, 40026, Italy

Location

Unknown Facility

Modena, Emilia-Romagna, 41100, Italy

Location

Unknown Facility

Parma, Emilia-Romagna, 43100, Italy

Location

Unknown Facility

Pordenone, Friuli Venezia Giulia, 33170, Italy

Location

Unknown Facility

Albano Laziale, Lazio, 00041, Italy

Location

Unknown Facility

Rome, Lazio, 00128, Italy

Location

Unknown Facility

Rome, Lazio, 00157, Italy

Location

Unknown Facility

Rome, Lazio, 00185, Italy

Location

Unknown Facility

Rome, Lazio, 00189, Italy

Location

Unknown Facility

Sora, Lazio, 03039, Italy

Location

Unknown Facility

Viterbo, Lazio, 01100, Italy

Location

Unknown Facility

Genoa, Liguria, 16132, Italy

Location

Unknown Facility

La Spezia, Liguria, 19100, Italy

Location

Unknown Facility

Savona, Liguria, Italy

Location

Unknown Facility

Bergamo, Lombardy, 24121, Italy

Location

Unknown Facility

Brescia, Lombardy, 25124, Italy

Location

Unknown Facility

Cremona, Lombardy, 26100, Italy

Location

Unknown Facility

Lecco, Lombardy, 23900, Italy

Location

Unknown Facility

Milan, Lombardy, 20099, Italy

Location

Unknown Facility

Milan, Lombardy, 20142, Italy

Location

Unknown Facility

Monza, Lombardy, 20900, Italy

Location

Unknown Facility

Pavia, Lombardy, 27100, Italy

Location

Unknown Facility

S. Fermo Della Battaglia (CO), Lombardy, 22020, Italy

Location

Unknown Facility

Saronno, Lombardy, 21047, Italy

Location

Unknown Facility

Varese, Lombardy, 21100, Italy

Location

Unknown Facility

Cuneo, Piedmont, 12100, Italy

Location

Unknown Facility

Novara, Piedmont, 28100, Italy

Location

Unknown Facility

Orbassano, Piedmont, 10043, Italy

Location

Unknown Facility

Ponderano (BI), Piedmont, 13875, Italy

Location

Unknown Facility

Turin, Piedmont, 10126, Italy

Location

Unknown Facility

Turin, Piedmont, 10153, Italy

Location

Unknown Facility

Cagliari, Sardinia, 09121, Italy

Location

Unknown Facility

Sassari, Sardinia, 07100, Italy

Location

Unknown Facility

Catania, Sicily, 95123, Italy

Location

Unknown Facility

Cefalù, Sicily, 90015, Italy

Location

Unknown Facility

Messina, Sicily, 98125, Italy

Location

Unknown Facility

Messina, Sicily, 98158, Italy

Location

Unknown Facility

Palermo, Sicily, 90100, Italy

Location

Unknown Facility

Taormina, Sicily, 98030, Italy

Location

Unknown Facility

Vimercate, Sicily, 20059, Italy

Location

Unknown Facility

Fano, The Marches, 61032, Italy

Location

Unknown Facility

Fermo, The Marches, 63023, Italy

Location

Unknown Facility

Macerata, The Marches, 62100, Italy

Location

Unknown Facility

Grosseto, Tuscany, 58100, Italy

Location

Unknown Facility

Lido di Camaiore, Tuscany, 55043, Italy

Location

Unknown Facility

Livorno, Tuscany, 57100, Italy

Location

Unknown Facility

Pontedera, Tuscany, 56025, Italy

Location

Unknown Facility

Siena, Tuscany, 53100, Italy

Location

Unknown Facility

Perugia, Umbria, 06156, Italy

Location

Unknown Facility

Cona (Ferrara), Veneto, 44124, Italy

Location

Unknown Facility

Este, Veneto, 35042, Italy

Location

Unknown Facility

Este (PD), Veneto, 35042, Italy

Location

Unknown Facility

Mirano, Veneto, 30035, Italy

Location

Unknown Facility

Montecchio Maggiore, Veneto, 36075, Italy

Location

Unknown Facility

Padua, Veneto, 35128, Italy

Location

Unknown Facility

Rovigo, Veneto, 45100, Italy

Location

Unknown Facility

Treviso, Veneto, 31100, Italy

Location

Related Publications (1)

  • Lonardi S, Nasti G, Fagnani D, Gemma D, Ciuffreda L, Granetto C, Lucchesi S, Ballestrero A, Biglietto M, Proserpio I, Bergamo F, Proietti E, Tonini G. Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. Tumori. 2019 Jun;105(3):243-252. doi: 10.1177/0300891619834126. Epub 2019 Mar 11.

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Clinical Trials

    Hoffmann-La Roche

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 29, 2012

First Posted

May 31, 2012

Study Start

June 1, 2012

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

November 2, 2016

Record last verified: 2016-11

Locations